{"entity":{"type":"insider","cik":"0001532230","url":"/insider/0001532230","json_url":"/insider/0001532230.json","name":"Milligan John C.K. IV","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":28,"n_filings":16,"first":"2014-01-30","last":"2021-05-12","span_basis":"filed_date"},"name_variants":[{"name":"Milligan John C.K. IV","source":"filing","n_filings":16,"first_seen":"2014-01-30","last_seen":"2021-05-12"}],"transactions":[{"id":4597804,"accession":"0001387131-21-005567","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001387131-21-005567","line_url":"/filing/0001387131-21-005567#line-2","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Officer (Secretary/CEO of subsidiary)","role_mark":"O","role_mark_label":"Officer (Secretary/CEO of subsidiary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Secretary/CEO of subsidiary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":44252.0,"shares_display":"44,252","price_per_share":1.04,"price_display":"1.04","price_state":"stated","total_value":46022.08,"total_display":"46,022.08","total_whole":"46,022","shares_owned_after":1752703.0,"shares_owned_after_display":"1,752,703","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-11","filed_date":"2021-05-12","scope":"insider"},{"id":8742074,"accession":"0001387131-19-007990","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001387131-19-007990","line_url":"/filing/0001387131-19-007990#line-1","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":72000.0,"shares_display":"72,000","price_per_share":2.75,"price_display":"2.75","price_state":"stated","total_value":198000.0,"total_display":"198,000.00","total_whole":"198,000","shares_owned_after":1544419.0,"shares_owned_after_display":"1,544,419","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-10-25","filed_date":"2019-10-29","scope":"insider"},{"id":8401386,"accession":"0001387131-19-007992","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001387131-19-007992","line_url":"/filing/0001387131-19-007992#line-1","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":72000.0,"shares_display":"72,000","price_per_share":2.75,"price_display":"2.75","price_state":"stated","total_value":198000.0,"total_display":"198,000.00","total_whole":"198,000","shares_owned_after":1544419.0,"shares_owned_after_display":"1,544,419","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-10-25","filed_date":"2019-10-29","scope":"insider"},{"id":7889635,"accession":"0001387131-19-006246","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001387131-19-006246","line_url":"/filing/0001387131-19-006246#line-1","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":2.93,"price_display":"2.93","price_state":"stated","total_value":29300.0,"total_display":"29,300.00","total_whole":"29,300","shares_owned_after":3582373.0,"shares_owned_after_display":"3,582,373","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-16","filed_date":"2019-08-19","scope":"insider"},{"id":7794952,"accession":"0001387131-19-006150","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001387131-19-006150","line_url":"/filing/0001387131-19-006150#line-1","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15000.0,"shares_display":"15,000","price_per_share":3.16,"price_display":"3.16","price_state":"stated","total_value":47400.0,"total_display":"47,400.00","total_whole":"47,400","shares_owned_after":3572373.0,"shares_owned_after_display":"3,572,373","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-08-12","filed_date":"2019-08-14","scope":"insider"},{"id":6027389,"accession":"0001387131-18-006855","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001387131-18-006855","line_url":"/filing/0001387131-18-006855#line-4","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":129127.0,"shares_display":"129,127","price_per_share":3.637,"price_display":"3.64","price_state":"stated","total_value":469634.899,"total_display":"469,634.90","total_whole":"469,635","shares_owned_after":1472419.0,"shares_owned_after_display":"1,472,419","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-18","filed_date":"2018-12-19","scope":"insider"},{"id":6027384,"accession":"0001387131-18-006855","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001387131-18-006855","line_url":"/filing/0001387131-18-006855#line-2","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":129000.0,"shares_display":"129,000","price_per_share":3.75,"price_display":"3.75","price_state":"stated","total_value":483750.0,"total_display":"483,750.00","total_whole":"483,750","shares_owned_after":1472419.0,"shares_owned_after_display":"1,472,419","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-17","filed_date":"2018-12-19","scope":"insider"},{"id":6433203,"accession":"0001387131-18-006632","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001387131-18-006632","line_url":"/filing/0001387131-18-006632#line-4","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":129000.0,"shares_display":"129,000","price_per_share":4.57,"price_display":"4.57","price_state":"stated","total_value":589530.0,"total_display":"589,530.00","total_whole":"589,530","shares_owned_after":1472419.0,"shares_owned_after_display":"1,472,419","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-06","filed_date":"2018-12-06","scope":"insider"},{"id":6433199,"accession":"0001387131-18-006632","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001387131-18-006632","line_url":"/filing/0001387131-18-006632#line-2","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":129000.0,"shares_display":"129,000","price_per_share":4.978,"price_display":"4.98","price_state":"stated","total_value":642162.0,"total_display":"642,162.00","total_whole":"642,162","shares_owned_after":1472419.0,"shares_owned_after_display":"1,472,419","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-04","filed_date":"2018-12-06","scope":"insider"},{"id":6460071,"accession":"0001387131-18-006478","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001387131-18-006478","line_url":"/filing/0001387131-18-006478#line-4","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":129128.0,"shares_display":"129,128","price_per_share":5.034,"price_display":"5.03","price_state":"stated","total_value":650030.352,"total_display":"650,030.35","total_whole":"650,030","shares_owned_after":1472419.0,"shares_owned_after_display":"1,472,419","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-29","filed_date":"2018-11-30","scope":"insider"},{"id":6460067,"accession":"0001387131-18-006478","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001387131-18-006478","line_url":"/filing/0001387131-18-006478#line-2","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":129000.0,"shares_display":"129,000","price_per_share":4.886,"price_display":"4.89","price_state":"stated","total_value":630294.0,"total_display":"630,294.00","total_whole":"630,294","shares_owned_after":1472419.0,"shares_owned_after_display":"1,472,419","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-28","filed_date":"2018-11-30","scope":"insider"},{"id":6433194,"accession":"0001387131-18-006314","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001387131-18-006314","line_url":"/filing/0001387131-18-006314#line-4","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":129000.0,"shares_display":"129,000","price_per_share":4.989,"price_display":"4.99","price_state":"stated","total_value":643581.0,"total_display":"643,581.00","total_whole":"643,581","shares_owned_after":1472419.0,"shares_owned_after_display":"1,472,419","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-15","filed_date":"2018-11-16","scope":"insider"},{"id":6433190,"accession":"0001387131-18-006314","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001387131-18-006314","line_url":"/filing/0001387131-18-006314#line-2","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":129000.0,"shares_display":"129,000","price_per_share":4.819,"price_display":"4.82","price_state":"stated","total_value":621651.0,"total_display":"621,651.00","total_whole":"621,651","shares_owned_after":1472419.0,"shares_owned_after_display":"1,472,419","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-14","filed_date":"2018-11-16","scope":"insider"},{"id":6278396,"accession":"0001387131-18-005637","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001387131-18-005637","line_url":"/filing/0001387131-18-005637#line-4","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":125000.0,"shares_display":"125,000","price_per_share":5.37,"price_display":"5.37","price_state":"stated","total_value":671250.0,"total_display":"671,250.00","total_whole":"671,250","shares_owned_after":1472419.0,"shares_owned_after_display":"1,472,419","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-10-24","filed_date":"2018-10-25","scope":"insider"},{"id":6278391,"accession":"0001387131-18-005637","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001387131-18-005637","line_url":"/filing/0001387131-18-005637#line-2","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":125000.0,"shares_display":"125,000","price_per_share":5.33,"price_display":"5.33","price_state":"stated","total_value":666250.0,"total_display":"666,250.00","total_whole":"666,250","shares_owned_after":1472419.0,"shares_owned_after_display":"1,472,419","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-10-23","filed_date":"2018-10-25","scope":"insider"},{"id":6212835,"accession":"0001387131-18-005414","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001387131-18-005414","line_url":"/filing/0001387131-18-005414#line-4","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":125000.0,"shares_display":"125,000","price_per_share":5.757,"price_display":"5.76","price_state":"stated","total_value":719625.0,"total_display":"719,625.00","total_whole":"719,625","shares_owned_after":1472419.0,"shares_owned_after_display":"1,472,419","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-10-10","filed_date":"2018-10-11","scope":"insider"},{"id":6212827,"accession":"0001387131-18-005414","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001387131-18-005414","line_url":"/filing/0001387131-18-005414#line-2","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":125000.0,"shares_display":"125,000","price_per_share":5.945,"price_display":"5.94","price_state":"stated","total_value":743125.0,"total_display":"743,125.00","total_whole":"743,125","shares_owned_after":1472419.0,"shares_owned_after_display":"1,472,419","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-10-09","filed_date":"2018-10-11","scope":"insider"},{"id":6212820,"accession":"0001387131-18-005028","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001387131-18-005028","line_url":"/filing/0001387131-18-005028#line-4","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":125000.0,"shares_display":"125,000","price_per_share":6.776,"price_display":"6.78","price_state":"stated","total_value":847000.0,"total_display":"847,000.00","total_whole":"847,000","shares_owned_after":1472419.0,"shares_owned_after_display":"1,472,419","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-09-26","filed_date":"2018-09-27","scope":"insider"},{"id":6212806,"accession":"0001387131-18-005028","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001387131-18-005028","line_url":"/filing/0001387131-18-005028#line-2","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":125000.0,"shares_display":"125,000","price_per_share":6.778,"price_display":"6.78","price_state":"stated","total_value":847250.0,"total_display":"847,250.00","total_whole":"847,250","shares_owned_after":1472419.0,"shares_owned_after_display":"1,472,419","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-09-25","filed_date":"2018-09-27","scope":"insider"},{"id":6502603,"accession":"0001387131-18-004676","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001387131-18-004676","line_url":"/filing/0001387131-18-004676#line-6","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":125000.0,"shares_display":"125,000","price_per_share":6.126,"price_display":"6.13","price_state":"stated","total_value":765750.0,"total_display":"765,750.00","total_whole":"765,750","shares_owned_after":1472419.0,"shares_owned_after_display":"1,472,419","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-09-11","filed_date":"2018-09-12","scope":"insider"},{"id":6502598,"accession":"0001387131-18-004676","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001387131-18-004676","line_url":"/filing/0001387131-18-004676#line-4","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":125000.0,"shares_display":"125,000","price_per_share":6.065,"price_display":"6.06","price_state":"stated","total_value":758125.0,"total_display":"758,125.00","total_whole":"758,125","shares_owned_after":1472419.0,"shares_owned_after_display":"1,472,419","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-09-10","filed_date":"2018-09-12","scope":"insider"},{"id":6445359,"accession":"0001387131-14-001136","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001387131-14-001136","line_url":"/filing/0001387131-14-001136#line-1","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President/Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President/Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":353412.0,"shares_display":"353,412","price_per_share":6.6971,"price_display":"6.70","price_state":"stated","total_value":2366835.5052,"total_display":"2,366,835.51","total_whole":"2,366,836","shares_owned_after":3892187.0,"shares_owned_after_display":"3,892,187","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-03-26","filed_date":"2014-03-28","scope":"insider"},{"id":6416249,"accession":"0001387131-14-000686","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001387131-14-000686","line_url":"/filing/0001387131-14-000686#line-3","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8400.0,"shares_display":"8,400","price_per_share":6.5285,"price_display":"6.53","price_state":"stated","total_value":54839.4,"total_display":"54,839.40","total_whole":"54,839","shares_owned_after":6318018.0,"shares_owned_after_display":"6,318,018","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-02-26","filed_date":"2014-02-26","scope":"insider"},{"id":6416246,"accession":"0001387131-14-000686","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001387131-14-000686","line_url":"/filing/0001387131-14-000686#line-2","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8300.0,"shares_display":"8,300","price_per_share":6.1587,"price_display":"6.16","price_state":"stated","total_value":51117.21,"total_display":"51,117.21","total_whole":"51,117","shares_owned_after":6326418.0,"shares_owned_after_display":"6,326,418","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-02-25","filed_date":"2014-02-26","scope":"insider"},{"id":6416242,"accession":"0001387131-14-000686","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001387131-14-000686","line_url":"/filing/0001387131-14-000686#line-1","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8300.0,"shares_display":"8,300","price_per_share":6.2331,"price_display":"6.23","price_state":"stated","total_value":51734.73,"total_display":"51,734.73","total_whole":"51,735","shares_owned_after":6334718.0,"shares_owned_after_display":"6,334,718","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-02-24","filed_date":"2014-02-26","scope":"insider"},{"id":7058772,"accession":"0001387131-14-000345","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001387131-14-000345","line_url":"/filing/0001387131-14-000345#line-3","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President, Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8400.0,"shares_display":"8,400","price_per_share":6.4944,"price_display":"6.49","price_state":"stated","total_value":54552.96,"total_display":"54,552.96","total_whole":"54,553","shares_owned_after":6343018.0,"shares_owned_after_display":"6,343,018","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-01-30","filed_date":"2014-01-30","scope":"insider"},{"id":7058770,"accession":"0001387131-14-000345","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001387131-14-000345","line_url":"/filing/0001387131-14-000345#line-2","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President, Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8300.0,"shares_display":"8,300","price_per_share":6.0301,"price_display":"6.03","price_state":"stated","total_value":50049.83,"total_display":"50,049.83","total_whole":"50,050","shares_owned_after":6351418.0,"shares_owned_after_display":"6,351,418","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-01-29","filed_date":"2014-01-30","scope":"insider"},{"id":7058765,"accession":"0001387131-14-000345","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001387131-14-000345","line_url":"/filing/0001387131-14-000345#line-1","is_derivative":false,"issuer_cik":"0000025743","issuer_name":"TherapeuticsMD, Inc.","issuer_ticker":"TXMD","issuer_name_source":null,"issuer_url":"/issuer/0000025743","owner_cik":"0001532230","owner_name":"Milligan John C.K. IV","owner_display_name":"Milligan John C.K. IV","owner_url":"/insider/0001532230","role":"Director, Officer (President, Secretary)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President, Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8300.0,"shares_display":"8,300","price_per_share":5.9416,"price_display":"5.94","price_state":"stated","total_value":49315.28,"total_display":"49,315.28","total_whole":"49,315","shares_owned_after":6359718.0,"shares_owned_after_display":"6,359,718","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-01-28","filed_date":"2014-01-30","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":28,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":4,"open_market":true},{"code":"S","label":"Open-market sale","n":24,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":28},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000025743","name":"TherapeuticsMD, Inc.","url":"/issuer/0000025743","role":"Director, Officer (Secretary/CEO of subsidiary)","n_filings":16,"first_seen":"2014-01-30","last_seen":"2021-05-12"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001532230","retrieved_at":"2026-08-24T14:44:32+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}